Supplied under the model designations PE-VG-API-200-LV and PE-VG-API-200-HV, the product is a veterinary-grade phthalate diester in which the ester content, monophthalate content, free alcohol content, water content, and acid value are controlled to pharmaceutical release limits rather than to plasticizer-grade acceptance ranges. The low-viscosity designation corresponds to the diethyl phthalate ester, CAS 84-66-2; the high-viscosity designation corresponds to the dibutyl phthalate ester, CAS 84-74-2. Both are clear, colourless to pale-yellow oily liquids with no visible particulate matter when examined under white light against a black background. Typical release data include ester content by gas chromatography after split injection, with a normalized area percentage of ≥99.0% for the low-viscosity grade and ≥98.5% for the high-viscosity grade; water content by Karl Fischer titration, Ph. Eur. 2.5.12, limited to ≤0.2%; acid value limited to ≤0.5 mg KOH/g; density at 20 °C between 1.117 g/cm³ and 1.121 g/cm³ for the low-viscosity grade; and refractive index at 20 °C between 1.500 and 1.505. The product is supplied against a veterinary API specification, not against the wider release windows typically used for technical-grade phthalate esters in polymer plasticizer applications.

Because the low-viscosity ester remains liquid at normal tablet-room temperatures, direct addition to a tablet or capsule blend is limited to free-liquid fractions below approximately 3% w/w; higher fractions require adsorption onto a suitable carrier before blending. Precipitated silica with an oil absorption number of 200–300 g/100 g is preferred because its internal pore volume immobilizes the ester without forming a continuous surface film. When adsorption is performed in a horizontal ploughshare mixer at fill volumes between 30% and 60%, the carrier-to-ester mass ratio is adjusted to yield a dry-appearing free-flowing adsorbate with loss on drying below 1.0%. Failure modes observed on production lines include granule caking on 80-mesh screens when the liquid load exceeds the carrier’s oil absorption capacity, and dose-weight variability outside the 5.0% relative standard deviation limit when free liquid remains. For tablets, blend uniformity is assessed according to Ph. Eur. 2.9.40 or USP <905>.

How Are Residual Solvents and Impurities Controlled Differently from Excipient Grades?

Residual solvent control follows VICH GL18 with limits aligned to the ICH Q3C option 1 approach. For the low-viscosity ester, benzene is limited to 2 ppm, methanol and ethanol are treated as Class 3 solvents with combined limits justified by cumulative daily intake, and the total unspecified chromatographic peak area is limited to 0.10% by gas chromatography. The high-viscosity ester adds a limit of 0.3% for n-butanol as a process marker. Heavy metals are controlled to 10 ppm by the Ph. Eur. 2.4.8 limit test or an equivalent closed-vessel digestion with inductively coupled plasma optical emission spectrometry. This differs from plasticizer-grade material, where phthalic acid may be tolerated at 0.1% or higher, and where the free alcohol content is not routinely reported. The veterinary API specification requires phthalic acid below 0.05% and free alcohol below 0.1% for the low-viscosity grade, both determined by acidimetric or gas chromatographic methods described in the supplier’s current pharmacopoeial monograph.

Stability under ICH/VICH conditions is monitored by acid value and ester content. In closed high-density polyethylene containers with induction-sealed polypropylene closures at 25 °C/60% RH, both grades remain within release limits for 36 months. At 40 °C/75% RH, the low-viscosity grade shows an acid value increase of 0.10–0.20 mg KOH/g over 6 months, while water content remains below 0.3%. This oxidative-hydrolytic drift is the primary stability-limiting pathway and requires exclusion of moisture and peroxides from the container headspace. The high-viscosity grade is less prone to evaporative loss but more sensitive to cold storage because viscosity increases sufficiently at 15 °C and below to interfere with automated filling and transfer.

Solid Dosage-Form Conversion Limits on Carrier Adsorption

Tablets containing adsorbed phthalate ester are prepared by first forming a carrier-adsorbate intermediate and then blending with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. The adsorbate fraction is typically limited to 25% of the final tablet mass because higher fractions reduce tensile strength below 1.0 MPa as measured by diametral compression, and prolong disintegration in purified water at 37 °C beyond 30 min when tested according to Ph. Eur. 2.9.1. Direct compression on a rotary tablet press with compaction force between 8 kN and 20 kN is possible when the adsorbate has a Hausner ratio below 1.25 and a Carr index below 20%; outside these boundaries, flow from the feed frame becomes erratic and die fill variability increases. Capsule filling on an automatic dosator machine requires the same adsorbed intermediate, because free liquid ester at more than 3% w/w deforms hard gelatin shells and leads to leakage at the cap-body junction.

For powders and granules, the low-viscosity ester is often sprayed onto a fluid-bed granulator charge in a diluted form. The spray solution is prepared in anhydrous ethanol or isopropanol at a concentration of 10–20% w/w, using a two-fluid nozzle with atomizing air pressure between 1.5 bar and 3.0 bar. Inlet air temperature is held between 30 °C and 45 °C to avoid thermal ester hydrolysis; outlet air dew point above 8 °C indicates that drying capacity is inadequate. Published data for this specific configuration is limited, so the spray-rate upper boundary must be established by stepwise trials because excessive wetting produces agglomerates with a bimodal particle-size distribution and subsequent content uniformity failure under Ph. Eur. 2.9.40 or USP <905>.

When Aqueous-Insoluble Esters Are Processed into Injectable Solutions

Injectable formulations are restricted to the low-viscosity diethyl phthalate ester unless solubility data in the selected non-aqueous vehicle demonstrate otherwise. Terminal sterilization by filtration through a 0.22 µm hydrophobic membrane is appropriate because the undiluted ester is not aqueous and because moist-heat sterilization above 121 °C risks ester hydrolysis at the container surface. The filter is pre-wetted with the anhydrous vehicle, and the filtrate is collected in depyrogenated glass ampoules or vials with butyl rubber stoppers. Bacterial endotoxin control follows Ph. Eur. 2.6.14 or USP <85>; for injectable-grade material, the limit is commonly set at 0.5 EU/mg for low-volume parenterals, but the final limit must be assigned from the maximum recommended dose and the species-specific veterinary acceptance criterion. Particulate matter must meet USP <788> for small-volume injections, using the light obscuration method with limits of 6000 particles per container for particles ≥10 µm and 600 particles per container for particles ≥25 µm.

The main processing conflict in solutions is solvent selection. The ester is miscible with many alcohols, ketones, and aromatic hydrocarbons but sparingly dispersed in water; aqueous dilution cannot be used as a primary vehicle unless a co-solvent system has been validated. When water-containing veterinary solutions are required, a ternary mixture of propylene glycol, ethanol, and purified water may be used, but phase separation occurs below the cosolvent threshold; the threshold must be determined by constructing a pseudo-ternary phase diagram at the intended storage temperature. Published data for this specific configuration is limited, and each formulation must be evaluated under ICH Q1B freeze-thaw cycling. Polyvinyl chloride administration tubing is avoided because the ester may extract plasticizer from the tubing into the solution; polypropylene or polyurethane administration sets are used where material compatibility has been confirmed.

Medicated premix production uses the high-viscosity ester because its lower vapour pressure reduces evaporative loss during feed pelleting at temperatures between 60 °C and 80 °C. The ester is first dispersed onto a mineral carrier such as precipitated silica or ground limestone; a V-blender or double-cone blender at 50% fill volume and a blending time of 10–20 min is used to achieve a coefficient of variation below 5.0% for the active marker. Sampling is performed at 10 points per batch, and the material is discharged into low-permeability aluminium-foil-lined bags because the ester can migrate through low-density polyethylene liners within 28 days at ambient warehouse conditions. Published data for this specific configuration is limited; the migration rate should be confirmed by extractables testing on the final packaging system.

Compared with solid-state veterinary APIs, the liquid phthalate ester requires an additional adsorption or dispersion unit operation before tableting or encapsulation. This is the principal processing difference; it shifts the mixing burden from the final blend to the carrier-adsorbate intermediate. Compared with other liquid veterinary formulation components such as benzyl alcohol or propylene glycol, the phthalate ester has a higher log P and lower water miscibility, which changes the cleaning strategy. Hot water alone is insufficient; a two-step cleaning sequence with an alkaline detergent followed by an isopropanol rinse is required to achieve visual and analytical residue clearance. The cleaned contact surfaces are sampled and tested by gas chromatography with a reporting threshold no greater than 10 ppm of the ester.

The designation as an API is retained for contract-manufacturing and regulatory file purposes only where the product is defined as the active constituent in the receiving veterinary marketing authorization. The product is not automatically interchangeable with a human pharmaceutical excipient grade, and the supplier does not assign a therapeutic indication independently of the finished-product authorization. For markets in which the ester is used as a formulation component rather than as the active constituent, the same limited impurity profile and residual solvent data are supplied to support the veterinary drug master file or the marketing authorization variation.